Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells.

Nepstad I, Hatfield KJ, Grønningsæter IS, Aasebø E, Hernandez-Valladares M, Hagen KM, Rye KP, Berven FS, Selheim F, Reikvam H, Bruserud Ø.

Signal Transduct Target Ther. 2019 Jun 19;4:20. doi: 10.1038/s41392-019-0050-0. eCollection 2019.

2.

CDC25 Inhibition in Acute Myeloid Leukemia-A Study of Patient Heterogeneity and the Effects of Different Inhibitors.

Brenner AK, Reikvam H, Rye KP, Hagen KM, Lavecchia A, Bruserud Ø.

Molecules. 2017 Mar 11;22(3). pii: E446. doi: 10.3390/molecules22030446.

3.

Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome.

Kittang AO, Kordasti S, Sand KE, Costantini B, Kramer AM, Perezabellan P, Seidl T, Rye KP, Hagen KM, Kulasekararaj A, Bruserud Ø, Mufti GJ.

Oncoimmunology. 2015 Jun 24;5(2):e1062208. eCollection 2016 Feb.

4.

The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells.

Reikvam H, Brenner AK, Hagen KM, Liseth K, Skrede S, Hatfield KJ, Bruserud Ø.

Stem Cell Res. 2015 Nov;15(3):530-541. doi: 10.1016/j.scr.2015.09.008. Epub 2015 Sep 25.

5.

Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation.

Bruserud Ø, Reikvam H, Fredly H, Skavland J, Hagen KM, van Hoang TT, Brenner AK, Kadi A, Astori A, Gjertsen BT, Pendino F.

Oncotarget. 2015 Feb 20;6(5):2794-811.

6.

CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia.

Astori A, Fredly H, Aloysius TA, Bullinger L, Mansat-De Mas V, de la Grange P, Delhommeau F, Hagen KM, Récher C, Dusanter-Fourt I, Knappskog S, Lillehaug JR, Pendino F, Bruserud Ø.

Oncotarget. 2013 Sep;4(9):1438-48.

Supplemental Content

Loading ...
Support Center